Fulcrum Therapeutics, Inc. Q3 2025 Earnings Recap

Fulcrum Therapeutics achieved promising advancements in its lead program, pociredir, for sickle cell disease, evidenced by positive trial data and completion of enrollment in the second dose cohort. The company's financial metrics show reduced losses as expenses decline.

Key Takeaways

• Pociredir exhibited a clinically meaningful increase in fetal hemoglobin and a reduction in vaso-occlusive crises, supporting its potential as a best-in-class treatment option.
• Enrollment in the 20-milligram dose cohort has been completed, with preliminary positive adherence rates from participating patients.
• Research and development expenses decreased to $14.3 million, reflecting cost management post-workforce reduction despite advancing key programs.
• Net loss narrowed to $19.6 million from $21.7 million in the prior year, indicating improved financial stability.
• The company has $200.6 million in cash, supporting ongoing clinical trials and future development plans.